Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020
DelveInsight Business Research LLP
7 min read
NASH Drug Pipeline Shows Promise as 95+ companies are working for Nonalcoholic Steatohepatitis Drug Development
Los Angeles, USA , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Nonalcoholic Steatohepatitis Drug Pipeline Analysis Review, 2020
NASH Drug Pipeline Shows Promise as 95+ companies are working for Nonalcoholic Steatohepatitis Drug Development
“Nonalcoholic Steatohepatitis (NASH) Pipeline Insight, 2020” by DelveInsight highlights the details around the NASH pipeline scenario, unmet needs, and NonAlcoholic Steatohepatitis therapeutic assessment of the key pipeline therapies.
95+ key companies are working to strengthen the Nonalcoholic Steatohepatitis pipeline including the AstraZeneca, Eli Lilly, Pfizer and several others.
Nonalcoholic Steatohepatitis market presents promising and a vast new product pipeline with pivotal trials, NME Projects and phase-advancing therapeutic candidates.
90+ Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include: GB1211, AZD2693, Tropifexor (LJN452), etc.
Collaborations and Deals
Pipeline Drug Profiles provided include:
Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
Phases of development
Mechanism of Action
Route of Administration
Companies involved including originator, licensing companies, developer, investors, and others
New molecular entity details
Drug designations and other special status provided by regulatory authorities
Market Drivers and Barriers
Nonalcoholic Steatohepatitis (NASH) is a form of fatty liver disease that can cause inflammation, and over the long term, can lead to scarring of the liver. Nonalcoholic Steatohepatitis symptoms include fatigue and pain in the upper right abdomen. There is no standard treatment for NASH patients, but lifestyle changes have influenced its progression.
ENYO Pharma develops EYP001, which is an orally bioavailable synthetic non-steroidal, non-bile acid FXR agonist small molecule that is also developed for NASH. FXR agonists could become the backbone of any future NASH therapies. The pioneering ENYO founding team discovered that FXR agonists interfere with the interaction between FXR and HBx, a hepatitis B viral protein essential for replicating the virus. It has demonstrated its efficacy in a Stelic mouse model (STAMTM) with a significant positive impact on most of the NASH key parameters (Fibrosis, Steatosis, Inflammation, Ballooning, triglycerides, and NAS). It differentiates from other FXR agonists with a potentially better C4/FGF19 balance.
Key Questions regarding Current NASH Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
What are the current options for Nonalcoholic Steatohepatitis treatment?
How many companies are developing therapies for the treatment of Nonalcoholic Steatohepatitis?
How many NASH emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Nonalcoholic Steatohepatitis?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Nonalcoholic Steatohepatitis market?
Which are the dormant and discontinued products and the reasons for the same?
What is the unmet need for current therapies for the treatment of NASH?
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Nonalcoholic Steatohepatitis therapies?
What are the key designations that have been granted for the emerging therapies for Nonalcoholic Steatohepatitis?
How many patents are granted and pending for the emerging therapies for the treatment of NASH?
DelveInsight's Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.
DelveInsight's Nonalcoholic Steatohepatitis (NASH) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Nonalcoholic Steatohepatitis (NASH) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight' s Non Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.
DelveInsight's Non Alcoholic Fatty Liver Disease (NAFLD) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Non Alcoholic Fatty Liver Disease (NAFLD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Non Alcoholic Fatty Liver Disease (NAFLD) Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Non Alcoholic Fatty Liver Disease (NAFLD).
Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Non Alcoholic Fatty Liver Disease (NAFLD) market.
DelveInsight's Hepatitis C Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.
About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
